Untangling Neuropathic Pain: How the SF-MPQ-2 Subscale Can Help
"A deep dive into how a modified pain assessment tool is paving the way for better understanding and management of Complex Regional Pain Syndrome."
Complex Regional Pain Syndrome (CRPS) presents a unique challenge in pain management. CRPS can emerge following trauma, surgery, or even spontaneously, making its origins diverse and often mysterious. While some individuals experience a resolution of symptoms within the first year, many others face persistent pain and disability, significantly impacting their quality of life. Understanding and accurately measuring the neuropathic components of this pain is crucial for effective treatment and improved patient outcomes.
Recognizing this need, the Special Interest Group for CRPS of the International Association for the Study of Pain (IASP) convened a working group dedicated to developing recommendations for outcome measurement in clinical studies. Their aim was to establish a core set of measures that could be consistently used across different studies and international collaborations, fostering better understanding and advancements in CRPS research.
One of the tools considered by this group was the Neuropathic Qualities subscale (NeQ) of the Short-Form McGill Pain Questionnaire-2 (SF-MPQ2). This subscale aims to capture the specific neuropathic features of pain, making it a valuable tool for researchers and clinicians alike. However, to ensure its reliability and validity, rigorous testing and analysis are essential. That’s exactly why researchers have been hard at work putting this tool to the test, and what we’re going to dive into today.
The Scale of Chronic and Neuropathic Pain
The CDC reported that 24.3% of U.S. adults had chronic pain in 2023, while 8.5% had high-impact chronic pain that frequently limited life or work activities during the previous three months. The figures come from the 2023 National Health Interview Survey. Neuropathic pain epidemiology has also been examined through analyses such as the UK Biobank pain questionnaire study. A Dutch study cited by the International Association for the Study of Pain estimated about 8 new neuropathic-pain cases per 1,000 person-years, while a German primary-care study found predominantly neuropathic pain in 37% of people with chronic low-back pain.
Why Structured Assessment Matters
Clinicians generally combine a patient’s description of symptoms with medical history and examination when evaluating suspected neuropathic pain. Structured questionnaires can help organize symptom reporting, but they should support rather than replace clinical judgment. Because neuropathic symptoms may vary in quality, intensity, and underlying cause, no single assessment approach is likely to capture every patient’s experience. The SF-MPQ-2 subscale is therefore best understood as one component of a broader evaluation.
From Historical Concept to Clinical Definition
Neuropathic pain was long associated with the post-Renaissance medical tradition, and John Fothergill was often credited with its first description in 1773. A review of medieval Persian medical writings, however, argues that the concept has medieval origins. Modern definitions describe neuropathic pain as pain caused by a lesion or disease of the somatosensory nervous system, with symptoms such as dysesthesia, paresthesia, hypoesthesia, and allodynia. Neurological disorders including multiple sclerosis can produce chronic pain through nerve damage, helping establish neuropathic pain as a distinct clinical problem.
What This Study Adds to the Conversation About Chronic Pain
A recent study delved into the psychometric properties of the SF-MPQ-2 Neuropathic Qualities subscale, specifically in individuals diagnosed with CRPS. The goal was to evaluate the subscale's validity, reliability, and responsiveness, ensuring it accurately captures the nuances of neuropathic pain experienced by these patients. The research team employed both classical psychometric evaluation and Rasch analysis—a statistical method that assesses how well the subscale measures the intended construct.
- Item-total correlations: Measures the relationship between individual items and the overall score.
- Unidimensionality: Assesses whether the subscale measures a single construct.
- Convergent construct validity: Examines the correlation with other measures expected to relate to neuropathic pain.
- Responsiveness: Evaluates the subscale's ability to detect changes in pain over time.
- Rasch analysis: A statistical method to evaluate and address data fitting challenges.
Research on Mechanisms and Treatment
Recent research continues to examine both the biology of neuropathic pain and ways to treat it. Nature reports that a new study linked chronic pain with accumulation of pathological tau protein in the hippocampus, neuronal atrophy, and cognitive impairment. A 2025 review describes chronic neuropathic pain as resulting from disease or damage within the somatosensory nervous system and surveys evolving treatment approaches. Together, these reports point to continued investigation of mechanisms, consequences, and therapies rather than a settled treatment landscape.
Persistent Treatment Challenges
Chronic neuropathic pain remains a significant unmet medical need despite progress in clinical research. Reviews describe it as among the most incapacitating forms of pain and note that it can arise from diabetic or non-diabetic neuropathies, surgery or trauma, herpes zoster, discal herniation, multiple sclerosis, and spinal-cord conditions. Reported treatment outcomes have been disappointing enough that new pharmacological agents continue to be developed and tested. At the same time, validated questionnaires have improved detection and assessment, but better measurement has not eliminated the broader management challenge.
Assessment Within a Broader Toolkit
The available material suggests that neuropathic-pain assessment is complementary rather than one-dimensional. Patient-reported questionnaires can structure symptom detection, while clinical evaluation is needed to interpret those symptoms in light of neurological disease or injury. Different causes may produce overlapping experiences, so a subscale can help characterize pain without independently establishing its cause. Its practical value is greatest when its results are considered alongside the rest of the clinical picture.
The Road Ahead
This study offers preliminary support for the validity and responsiveness of the NeQ subscale in individuals with CRPS. Rasch analysis further endorses its use as a stand-alone measure for neuropathic features, albeit with substantial background data transformations. Replication with larger samples is recommended to increase confidence in these findings. By continuing to refine and validate tools like the SF-MPQ-2 NeQ subscale, researchers and clinicians can work together to improve the assessment and treatment of neuropathic pain, ultimately enhancing the lives of those affected by CRPS and similar conditions.
A Focused Measure, Not a Complete Diagnosis
The sources collectively portray neuropathic pain as a complex condition with diverse causes, distinctive sensory qualities, and substantial effects on patients. A focused measure such as the SF-MPQ-2 neuropathic-pain subscale can make symptom patterns easier to document and discuss. It should not be treated as a standalone diagnosis or a substitute for evaluating the underlying neurological condition. Its role is to add structured information to individualized clinical care.
Expanding Treatments and the Care Market
The future treatment landscape is expected to include a growing pipeline of therapies for chronic neuropathic pain. A 2026 pipeline report describes the latest and future landscape of treatments, while market forecasts identify increasing demand for neuropathic-pain drugs and government initiatives as growth drivers. One forecast projects the neuropathic-pain market to reach USD 21.32 billion by 2035, up from USD 9.25 billion in 2026, at a 9.71% CAGR. These projections are forecasts rather than guaranteed outcomes, but they indicate substantial commercial and research interest.
Complex Causes and Uneven Care
Neuropathic pain can result from many conditions, including diabetes, trauma, surgery, herpes zoster, multiple sclerosis, and spinal disorders. This diversity can make consistent recognition and treatment difficult across healthcare settings. Persistent symptoms may also require repeated assessment as their severity and functional effects change. Structured symptom tools may help communication, but broader challenges in diagnosis, access, and long-term management remain.
Function, Relief, and Everyday Burden
A real-world analysis of permanent receiver-based peripheral nerve stimulation reported sustained pain reduction, no serious adverse events, and reduced healthcare utilization and costs in patients with chronic, intractable neuropathic pain of peripheral nerve origin. A related report characterized permanent peripheral nerve stimulation as safe and clinically effective in this population. Diabetes provides another example of the human burden: diabetic neuropathy risk rises with longer disease duration and poorer glycemic control, and sensory involvement can cause numbness, paresthesias, and pain. These findings emphasize why assessment should address both symptom quality and effects on daily life.